Professor | Ying Zhang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Ying Zhang
Contact Information	{'en': 'Email: ying.zhang (AT) pku.edu.cn', 'zh': '电子邮件：ying.zhang (AT) pku.edu.cn', 'de': 'E-Mail: ying.zhang (AT) pku.edu.cn'}
Language ability	English, Chinese
Province	Beijing

Upload Avatar (500 x 500)

Name

Ying Zhang

Contact Information

{'en': 'Email: ying.zhang (AT) pku.edu.cn', 'zh': '电子邮件：ying.zhang (AT) pku.edu.cn', 'de': 'E-Mail: ying.zhang (AT) pku.edu.cn'}

Language ability

English, Chinese

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Life Sciences
Academic Background & Achievements	2009-2016 PhD in Biomedical Sciences, University of Pennsylvania Perelman School of Medicine 2005-2009 Bachelor in Biological Sciences, Nankai University Awards: NIH K99/R00 Pathway to Independence Award, Department of Defense Breast Cancer Breakthrough Award, Cancer Research Institute Irvington Postdoctoral Fellowship
Work Experience	2022.07-present Researcher, Peking University College of Life Sciences 2022.07-present Researcher, Peking-Tsinghua Center for Life Sciences 2021.02-2022.06 Lecturer, Harvard Medical School/Boston Children's Hospital 2016.11-2021.02 Postdoctoral Researcher, Harvard Medical School/Boston Children's Hospital
Awards	2023 Boya Young Scholar, Peking University 2022 Bayer Scholar 2022 Yifang Scholar 2021-2022 NIH/National Cancer Institute K99/R00 Pathway to Independence Award 2019-2022 Department of Defense Breast Cancer Breakthrough Award 2018-2019 Cancer Research Institute Irvington Postdoctoral Fellowship 2016 Gutmann Presidential Leadership Award, University of Pennsylvania 2016 American Association of Immunologists Research Abstract Award 2014 American Cancer Society Scholar Award

University/Lab Affiliation and Title

Peking University

Faculty

Life Sciences

Academic Background & Achievements

2009-2016 PhD in Biomedical Sciences, University of Pennsylvania Perelman School of Medicine
2005-2009 Bachelor in Biological Sciences, Nankai University
Awards: NIH K99/R00 Pathway to Independence Award, Department of Defense Breast Cancer Breakthrough Award, Cancer Research Institute Irvington Postdoctoral Fellowship

Work Experience

2022.07-present Researcher, Peking University College of Life Sciences
2022.07-present Researcher, Peking-Tsinghua Center for Life Sciences
2021.02-2022.06 Lecturer, Harvard Medical School/Boston Children's Hospital
2016.11-2021.02 Postdoctoral Researcher, Harvard Medical School/Boston Children's Hospital

Awards

2023 Boya Young Scholar, Peking University
2022 Bayer Scholar
2022 Yifang Scholar
2021-2022 NIH/National Cancer Institute K99/R00 Pathway to Independence Award
2019-2022 Department of Defense Breast Cancer Breakthrough Award
2018-2019 Cancer Research Institute Irvington Postdoctoral Fellowship
2016 Gutmann Presidential Leadership Award, University of Pennsylvania
2016 American Association of Immunologists Research Abstract Award
2014 American Cancer Society Scholar Award

Areas of Focus	Tumor immunology and immunotherapy Tumor vaccine development Immunometabolic reprogramming in the tumor microenvironment Cellular inflammatory death and tumor immunotherapy
Publications	Tumor editing suppresses innate and adaptive anti-tumor immunity and is reversed by inhibiting DNA methylation, Zhang Y, Yeganeh PN, Zhang HW, Wang SY, Li ZYH, Gu BW, Lee DJ, Zhang ZB, Ploumakis A, Shi M, Wu H, Greer EL, Hide W, Lieberman J, 2024 Small molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity, Fontana P, Du. G, Zhang, Y, Zhang HW, Vora SM, Hu JJ, Shi M, Tufan AB, Healy LB, Xia SY, Lee DJ, Li ZYH, Flores PB, Ru H, Luo HR, Agudo J, Lieberman J, Wu H, 2024 Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown, Zhang Y, Xie X, Yeganeh PN, Lee DJ, Valle-Garcia D, Meza-Sosa KF, Junqueira C, Su J, Luo H, Hide W, Lieberman J, 2021 Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?, Zhang Z, Zhang Y, Judy Lieberman, 2021 Gasdermin E suppresses tumour growth by activating anti-tumour immunity, Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, Sengupta S, Yao Y, Wu H, Lieberman J, 2020 FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation, Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H, 2020 Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy, Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davies W, Xu W, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz J, Ertl HC, 2017 Aging: T cell metabolism within tumors, Zhang Y, Ertl HC, 2016 Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors, Zhang Y, Ertl HC, 2016 Starved and asphyxiated: how can CD8+T cells within a tumor microenvironment prevent tumor progression, Zhang Y, Ertl HC, 2016 The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on Melanoma-Driven CD8+T cell exhaustion, Zhang Y, Ertl HC, 2014 SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage, Meza-Sosa KF, Miao R, Navarro F, Zhang Z, Zhang Y, Hu JJ, Hartford C, Li X, Pedraza-Alva G, Pérez-Martínez L, Lal A, Wu H, Lieberman J, 2022 Targeting Stem-loop 1 of the SARS-CoV-2 5’UTR to suppress viral translation and Nsp1 evasion, Vora SM, Fontana P, Mao T, Leger V, Zhang Y, Fu TM, Lieberman J, Gehrke L, Shi M, Wang LF, Iwasaki A, Wu H, 2022

Areas of Focus

Tumor immunology and immunotherapy
Tumor vaccine development
Immunometabolic reprogramming in the tumor microenvironment
Cellular inflammatory death and tumor immunotherapy

Publications

Tumor editing suppresses innate and adaptive anti-tumor immunity and is reversed by inhibiting DNA methylation, Zhang Y, Yeganeh PN, Zhang HW, Wang SY, Li ZYH, Gu BW, Lee DJ, Zhang ZB, Ploumakis A, Shi M, Wu H, Greer EL, Hide W, Lieberman J, 2024
Small molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity, Fontana P, Du. G, Zhang, Y, Zhang HW, Vora SM, Hu JJ, Shi M, Tufan AB, Healy LB, Xia SY, Lee DJ, Li ZYH, Flores PB, Ru H, Luo HR, Agudo J, Lieberman J, Wu H, 2024
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown, Zhang Y, Xie X, Yeganeh PN, Lee DJ, Valle-Garcia D, Meza-Sosa KF, Junqueira C, Su J, Luo H, Hide W, Lieberman J, 2021
Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity?, Zhang Z, Zhang Y, Judy Lieberman, 2021
Gasdermin E suppresses tumour growth by activating anti-tumour immunity, Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, Sengupta S, Yao Y, Wu H, Lieberman J, 2020
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation, Hu JJ, Liu X, Xia S, Zhang Z, Zhang Y, Zhao J, Ruan J, Luo X, Lou X, Bai Y, Wang J, Hollingsworth LR, Magupalli VG, Zhao L, Luo HR, Kim J, Lieberman J, Wu H, 2020
Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy, Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davies W, Xu W, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz J, Ertl HC, 2017
Aging: T cell metabolism within tumors, Zhang Y, Ertl HC, 2016
Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors, Zhang Y, Ertl HC, 2016
Starved and asphyxiated: how can CD8+T cells within a tumor microenvironment prevent tumor progression, Zhang Y, Ertl HC, 2016
The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on Melanoma-Driven CD8+T cell exhaustion, Zhang Y, Ertl HC, 2014
SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage, Meza-Sosa KF, Miao R, Navarro F, Zhang Z, Zhang Y, Hu JJ, Hartford C, Li X, Pedraza-Alva G, Pérez-Martínez L, Lal A, Wu H, Lieberman J, 2022
Targeting Stem-loop 1 of the SARS-CoV-2 5’UTR to suppress viral translation and Nsp1 evasion, Vora SM, Fontana P, Mao T, Leger V, Zhang Y, Fu TM, Lieberman J, Gehrke L, Shi M, Wang LF, Iwasaki A, Wu H, 2022

Tumor Immunology Immunotherapy Vaccine Microenvironment Immunometabolic Reprogramming Cellular Inflammatory Death

Lu Jianfeng - Tongji University

Jing Yang - Peking University

Li Xiaodong - China Medical University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us